netrashetty
Netra Shetty
Allergan, Inc., is a global specialty pharmaceutical company. Their product ranges include ophthalmic pharmaceuticals, dermatology products, and neurological products.
Global in reach. Specialized in focus.
Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter consumer products that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.
Our focus fosters deep engagement with medical specialists and we make it our business to listen closely to their needs so that together we can advance patient care. We combine this strategic focus with a diversified approach that enables us to follow our research and development into new specialty areas where unmet needs are significant.
In partnership with the medical community, we bring scientific excellence and rigor to deliver leading products that improve patient outcomes. And, we go above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. We know we are successful when doctors and patients place their trust in our products and our company, when our employees excel and when our efforts make a meaningful difference in the lives of the patients and communities we serve.
We are pleased to offer a number of leading products, including: BOTOX® (onabotulinumtoxinA), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.03%, BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® family of dermal fillers, and the LAP-BAND® Adjustable Gastric Banding System. Please look through this Web site for more information, including Important Safety Information, about these products and our full portfolio of products.
Eye Care
With a heritage of nearly 60 years in discovering and developing new therapeutic agents to protect and preserve vision, eye care professionals and patients rely on Allergan products to treat a variety of eye conditions including glaucoma, dry eye, and external eye diseases. Today we are a global leader in this specialty area and continue for the past six years to be one of the fastest-growing eye care companies worldwide.1 Leading products in Allergan's eye care product portfolio include RESTASIS® ophthalmic emulsion, LUMIGAN® ophthalmic solution, OPTIVE™ Lubricant Eye Drops, and the REFRESH® Brand line of artificial tears.
Our robust research and development investment upholds our unwavering commitment to advancing eye care treatments. Back-of-the-eye diseases, such as macular edema, diabetic retinopathy and age-related macular degeneration, cause sight loss in millions of patients each year. Unfortunately, the prevalence of these diseases is increasing as the population ages. Over the next decade, major progress will be made in treating such retinal diseases and Allergan expects to be in the forefront of these advances.
Neurosciences
Allergan is a world leader in neuromodulator therapy and neurosciences. For nearly two decades, we have been committed to the research and clinical development of BOTOX® (onabotulinumtoxinA), one of the world's most versatile medicines, to help improve the physical well-being of people around the world who suffer from a variety of serious or debilitating disorders. BOTOX® is currently available in approximately 75 countries.
Building on our heritage, Allergan is now pursuing advanced research to develop "next-generation" neuromodulator therapies and other treatments for neurological conditions.
Indication
BOTOX® is a prescription medicine that is injected into muscles and used:
to treat increased muscle stiffness in elbow, wrist, and finger muscles with upper limb spasticity in people 18 years and older.
to treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in people 16 years and older.
to treat certain types of eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm) in people 12 years and older.
BOTOX® is also injected into the skin to treat the symptoms of severe underarm sweating (severe primary axillary hyperhidrosis) when medicines used on the skin (topical) do not work well enough in people 18 years and older.
It is not known whether BOTOX® is safe or effective for other types of muscle spasms or for severe sweating anywhere other than your armpits.
Important Safety Information
BOTOX® may cause serious side effects that can be life threatening. Call your doctor or get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX®:
Problems swallowing, speaking, or breathing, due to weakening of associated muscles,can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice (dysphonia), trouble saying words clearly (dysarthria), loss of bladder control, trouble breathing, trouble swallowing.
There has not been a confirmed serious case of spread of toxin effect away from the injection site when BOTOX® has been used at the recommended dose to treat severe underarm sweating, blepharospasm, or strabismus.
The dose of BOTOX® is not the same as, or comparable to, another botulinum toxin product.
Serious and/or immediate allergic reactions have been reported. These reactions include itchy rash, swelling, and shortness of breath. Tell your doctor or get medical help right away if you experience any such symptoms, further injection of BOTOX® should be discontinued.
Do not take BOTOX® if you: are allergic to any of the ingredients in BOTOX® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® or Dysport®; have a skin infection at the planned injection site.
Tell your doctor about all your muscle or nerve conditions such as amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease], myasthenia gravis or Lambert-Eaton syndrome as you may be at increased risk of serious side effects including severe dysphagia (difficulty swallowing) and respiratory compromise (difficulty breathing) from typical doses of BOTOX®.
Tell your doctor about all your medical conditions, including if you have: plans to have surgery; had surgery on your face; weakness of forehead muscles, such as trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (It is not known if BOTOX® can harm your unborn baby); are breast-feeding or plan to breastfeed (It is not known if BOTOX® passes into breast milk).
Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal products.
BOTOX® may cause loss of strength or general muscle weakness, or vision problems. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
Other side effects of BOTOX® include: dry mouth, discomfort or pain at the injection site, tiredness, headache, neck pain, and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids, swelling of your eyelids, and dry eyes.
Obesity Intervention
Allergan is committed to enabling patients to reach a natural healthy weight and to live an active lifestyle. Over the last 50 years, obesity has been increasing at an alarming rate and is now recognized by leading government health authorities, such as the Centers for Disease Control (CDC) and National Institutes of Health (NIH), as a disease. In the United States alone, obesity affects more than 60 million individuals1 and is considered the second leading cause of preventable death.2 Worldwide, approximately 1.6 billion adults are overweight, and it is estimated that obesity affects at least 400 million adults.3
Obesity is caused by a wide range of factors including genetics, metabolic disorders, physical and psychological issues, lifestyle, and poor nutrition. Millions of obese and overweight individuals first turn to diet, fitness and medication to lose weight; however, these efforts alone are often not enough to keep weight at a level that is optimal for good health. Surgery is another increasingly viable alternative for those with a Body Mass Index (BMI) of greater than 40. In fact, the number of bariatric surgeries in the United States is projected to reach approximately 400,000 annually by 2010.4
Allergan has joined the effort to fight the growing obesity epidemic with a portfolio of innovative medical devices to help achieve and support sustained weight loss, reduce health risks associated with obesity and help patients realize their goals for healthy living and wellness. The LAP-BAND® Adjustable Gastric Banding System is the first adjustable medical device for individualized weight loss and the first minimally invasive surgical approach approved in the United States by the U.S. Food and Drug Administration. Approved outside of the United States, Allergan's portfolio also includes the BIB™ Intragastric Balloon System, which is a non-surgical alternative for the treatment of obesity.
Given the serious immediate and long-term consequences of the global obesity epidemic, we are committed to programs to prevent obesity. In that quest, we are actively pursuing the development of next-generation products and technologies capable of providing high-quality, healthier, and less traumatic long-term weight-loss treatment solutions.
Medical Aesthetics
Thanks to the many scientific advances in medicine over the last century, people are living longer, healthier lives. Yet individuals may feel that their outside appearance doesn't always match the vibrancy they feel on the inside. Environmental damage and the natural aging process lead some to seek science-based options.
Allergan's Total Rejuvenation™ portfolio is where science and aesthetics meet. The portfolio provides medical specialists and their patients with the most comprehensive, science-based aesthetic product offerings available. With the Natrelle® Collection, Allergan offers the industry's widest range of silicone gel and saline breast implant options for women seeking to enhance or restore their breast shape and form. We offer a comprehensive, science-based facial aesthetic portfolio that includes BOTOX® Cosmetic (onabotulinumtoxinA); the JUVÉDERM® family of dermal filler products; and physician-dispensed skin care products.
As a world leader in medical aesthetics, Allergan is and will remain deeply committed to the Science of Rejuvenation™. This means providing medical specialists and patients with products and information backed by science so they can make the best-informed medical aesthetics choices possible based on their own individual needs and treatment goals.
Indication
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in people 18 to 65 years of age for a short period of time (temporary).
IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects that can be life threatening. Call your doctor or get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:
Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice (dysphonia), trouble saying words clearly (dysarthria), loss of bladder control, trouble breathing, trouble swallowing.
There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines.
The dose of BOTOX® Cosmetic is not the same as, or comparable to, another botulinum toxin product.
Serious and or immediate allergic reactions have been reported. These reactions include itchy rash, swelling, and shortness of breath. Tell your doctor or get medical help right away if you experience any such symptoms, further injection of BOTOX® Cosmetic should be discontinued.
Do not take BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® or Dysport®; have a skin infection at the planned injection site.
Tell your doctor about all your muscle or nerve conditions such as amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease], myasthenia gravis or Lambert-Eaton syndrome as you may be at increased risk of serious side effects including severe dysphagia (difficulty swallowing) and respiratory compromise (difficulty breathing) from typical doses of BOTOX® Cosmetic.
Tell your doctor about all your medical conditions, including if you have: plans to have surgery; had surgery on your face; weakness of forehead muscles, such as trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (It is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to breastfeed (It is not known if BOTOX® Cosmetic passes into breast milk).
Medical Dermatology
Facing the world is not always easy for patients suffering from serious skin disorders. Dedicated to meeting the needs of these patients and their physicians, Allergan has developed some of the most technologically advanced dermatology products to treat skin disease as well as enhance the appearance of healthy skin.
According to the National Institutes of Health, between 5.8 and 7.5 million Americans suffer from psoriasis1, which is a chronic skin disorder than can take many different forms. An estimated 80 percent of all people between the ages of 11 and 30 have acne outbreaks at some point.2 Our dermatology portfolio includes TAZORAC® (tazarotene), the first topical receptor selective retinoid approved for psoriasis.
Another common chronic condition affecting an estimated 7.8 million Americans is hyperhidrosis, which is the term for excessive sweating.3 Patients with hyperhidrosis produce an amount of sweat that far exceeds that needed to regulate body temperature. Our medical dermatology portfolio includes BOTOX® (onabotulinumtoxinA) for severe primary axillary hyperhidrosis (excessive underarm sweating) that is not adequately managed by topical agents.
Urologics
At Allergan, we recognize the serious implications of urologic disorders including overactive bladder (OAB), a medical condition that affects 33 million Americans and is only expected to grow in prevalence as the population ages.1 In 2007, Allergan created a dedicated Urologics division within the organization to focus on meeting the needs of urologists and their patients.
Allergan is investing significant resources to develop a product portfolio that addresses the full continuum of care for patients with OAB and other urological and genitourinary disorders. Allergan's current product in this portfolio is SANCTURA XR®, a once-daily medication for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency approved in 2007 by the U.S. Food and Drug Administration.
In addition to our current products for OAB, we are continuing to research and develop new treatments for urologic disorders. Globally, we are currently in Phase III clinical trials investigating the use of BOTOX® (onabotulinumtoxinA) for the treatment of neurogenic OAB - that is, OAB secondary to multiple sclerosis or spinal cord injury, or other neurologic dysfunction. And we are in the midst of Phase II clinical trials of BOTOX® for idiopathic OAB (in which the cause is unknown) – by far the most common form of the disorder. In addition, Allergan is studying the use of BOTOX® neurotoxin in a Phase II clinical trial for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia, a non-cancerous disease of the prostate that can interfere with urination and is one of the most common diseases among men.
roduct Prescribing and Labeling Information
ACULAR® (ketorolac tromethamine ophthalmic solution) 0.5% (PDF)
ACULAR LS® (ketorolac tromethamine ophthalmic solution) 0.4% (PDF)
ACUVAIL® (ketorolac tromethamine ophthalmic solution) 0.45% (PDF)
ACZONE® (dapsone) Gel 5% (PDF)
ALOCRIL® (nedocromil sodium ophthalmic solution) 2% (PDF)
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15% (PDF)
AVAGE® (tazarotene) Cream 0.1% (PDF)
AZELEX® (azelaic acid cream) 20% (PDF)
BETAGAN® (levobunolol hydrochloride ophthalmic solution, USP) 0.5% (PDF)
BLEPH®-10 (sulfacetamide sodium ophthalmic solution, USP) 10% (PDF)
BLEPHAMIDE® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% (PDF)
BLEPHAMIDE® (sulfacetamide sodium − prednisolone acetate ophthalmic suspension, USP) 10%/0.2% (PDF)
BOTOX® (onabotulinumtoxinA) (PDF)
BOTOX® Cosmetic (onabotulinumtoxinA) (PDF)
COMBIGAN® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% (PDF)
ELESTAT® (epinastine HCl ophthalmic solution) 0.05% (PDF)
FLUOROPLEX® (fluorouracil) 1% Topical Cream (PDF)
FML® (fluorometholone ophthalmic ointment) 0.1% (PDF)
FML® (fluorometholone ophthalmic suspension, USP) 0.1% (PDF)
FML FORTE® (fluorometholone ophthalmic suspension) 0.25% (PDF)
JUVÉDERM® Ultra and JUVÉDERM® Ultra Plus (PDF)
JUVÉDERM® Ultra XC (PDF)
JUVÉDERM® Ultra Plus XC (PDF)
LASTACAFT™ (alcaftadine ophthalmic solution) 0.25% (PDF)
LATISSE® (bimatoprost ophthalmic solution) 0.03% (PDF)
LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) (PDF)
OCUFEN® (flurbiprofen sodium ophthalmic solution, USP) 0.03% (PDF)
OCUFLOX® (ofloxacin ophthalmic solution) 0.3% (PDF)
OZURDEX® (dexamethasone intravitreal implant) 0.7 mg (PDF)
POLY-PRED® (prednisolone acetate, neomycin sulfate, polymyxin B sulfate ophthalmic suspension) 0.5%/0.35% (PDF)
POLYTRIM® (polymyxin B sulfate and trimethoprim ophthalmic solution, USP) (PDF)
PRED FORTE® (prednisolone acetate ophthalmic suspension, USP) 1% (PDF)
PRED MILD® (prednisolone acetate ophthalmic suspension, USP) 0.12% (PDF)
PRED-G® (gentamicin and prednisolone acetate ophthalmic ointment, USP) 0.3%/0.6% (PDF)
PRED-G® (gentamicin and prednisolone acetate ophthalmic suspension, USP) 0.3%/1.0% (PDF)
PREVAGE® MD (PDF)
REFRESH CONTACTS® Contact Lens Comfort Drops (PDF)
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% (PDF)
SANCTURA® (trospium chloride) (PDF)
SANCTURA XR® (trospium chloride extended release capsules) (PDF)
TAZORAC® (tazarotene) Cream 0.05% and 0.1% (PDF)
TAZORAC® (tazarotene) Gel 0.05% and 0.1% (PDF)
ZYMAR® (gatifloxacin ophthalmic solution) 0.3% (PDF)
ZYMAXID™ (gatifloxacin ophthalmic solution) 0.5% (PDF)
Global in reach. Specialized in focus.
Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter consumer products that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.
Our focus fosters deep engagement with medical specialists and we make it our business to listen closely to their needs so that together we can advance patient care. We combine this strategic focus with a diversified approach that enables us to follow our research and development into new specialty areas where unmet needs are significant.
In partnership with the medical community, we bring scientific excellence and rigor to deliver leading products that improve patient outcomes. And, we go above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. We know we are successful when doctors and patients place their trust in our products and our company, when our employees excel and when our efforts make a meaningful difference in the lives of the patients and communities we serve.
We are pleased to offer a number of leading products, including: BOTOX® (onabotulinumtoxinA), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.03%, BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® family of dermal fillers, and the LAP-BAND® Adjustable Gastric Banding System. Please look through this Web site for more information, including Important Safety Information, about these products and our full portfolio of products.
Eye Care
With a heritage of nearly 60 years in discovering and developing new therapeutic agents to protect and preserve vision, eye care professionals and patients rely on Allergan products to treat a variety of eye conditions including glaucoma, dry eye, and external eye diseases. Today we are a global leader in this specialty area and continue for the past six years to be one of the fastest-growing eye care companies worldwide.1 Leading products in Allergan's eye care product portfolio include RESTASIS® ophthalmic emulsion, LUMIGAN® ophthalmic solution, OPTIVE™ Lubricant Eye Drops, and the REFRESH® Brand line of artificial tears.
Our robust research and development investment upholds our unwavering commitment to advancing eye care treatments. Back-of-the-eye diseases, such as macular edema, diabetic retinopathy and age-related macular degeneration, cause sight loss in millions of patients each year. Unfortunately, the prevalence of these diseases is increasing as the population ages. Over the next decade, major progress will be made in treating such retinal diseases and Allergan expects to be in the forefront of these advances.
Neurosciences
Allergan is a world leader in neuromodulator therapy and neurosciences. For nearly two decades, we have been committed to the research and clinical development of BOTOX® (onabotulinumtoxinA), one of the world's most versatile medicines, to help improve the physical well-being of people around the world who suffer from a variety of serious or debilitating disorders. BOTOX® is currently available in approximately 75 countries.
Building on our heritage, Allergan is now pursuing advanced research to develop "next-generation" neuromodulator therapies and other treatments for neurological conditions.
Indication
BOTOX® is a prescription medicine that is injected into muscles and used:
to treat increased muscle stiffness in elbow, wrist, and finger muscles with upper limb spasticity in people 18 years and older.
to treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in people 16 years and older.
to treat certain types of eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm) in people 12 years and older.
BOTOX® is also injected into the skin to treat the symptoms of severe underarm sweating (severe primary axillary hyperhidrosis) when medicines used on the skin (topical) do not work well enough in people 18 years and older.
It is not known whether BOTOX® is safe or effective for other types of muscle spasms or for severe sweating anywhere other than your armpits.
Important Safety Information
BOTOX® may cause serious side effects that can be life threatening. Call your doctor or get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX®:
Problems swallowing, speaking, or breathing, due to weakening of associated muscles,can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice (dysphonia), trouble saying words clearly (dysarthria), loss of bladder control, trouble breathing, trouble swallowing.
There has not been a confirmed serious case of spread of toxin effect away from the injection site when BOTOX® has been used at the recommended dose to treat severe underarm sweating, blepharospasm, or strabismus.
The dose of BOTOX® is not the same as, or comparable to, another botulinum toxin product.
Serious and/or immediate allergic reactions have been reported. These reactions include itchy rash, swelling, and shortness of breath. Tell your doctor or get medical help right away if you experience any such symptoms, further injection of BOTOX® should be discontinued.
Do not take BOTOX® if you: are allergic to any of the ingredients in BOTOX® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® or Dysport®; have a skin infection at the planned injection site.
Tell your doctor about all your muscle or nerve conditions such as amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease], myasthenia gravis or Lambert-Eaton syndrome as you may be at increased risk of serious side effects including severe dysphagia (difficulty swallowing) and respiratory compromise (difficulty breathing) from typical doses of BOTOX®.
Tell your doctor about all your medical conditions, including if you have: plans to have surgery; had surgery on your face; weakness of forehead muscles, such as trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (It is not known if BOTOX® can harm your unborn baby); are breast-feeding or plan to breastfeed (It is not known if BOTOX® passes into breast milk).
Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal products.
BOTOX® may cause loss of strength or general muscle weakness, or vision problems. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
Other side effects of BOTOX® include: dry mouth, discomfort or pain at the injection site, tiredness, headache, neck pain, and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids, swelling of your eyelids, and dry eyes.
Obesity Intervention
Allergan is committed to enabling patients to reach a natural healthy weight and to live an active lifestyle. Over the last 50 years, obesity has been increasing at an alarming rate and is now recognized by leading government health authorities, such as the Centers for Disease Control (CDC) and National Institutes of Health (NIH), as a disease. In the United States alone, obesity affects more than 60 million individuals1 and is considered the second leading cause of preventable death.2 Worldwide, approximately 1.6 billion adults are overweight, and it is estimated that obesity affects at least 400 million adults.3
Obesity is caused by a wide range of factors including genetics, metabolic disorders, physical and psychological issues, lifestyle, and poor nutrition. Millions of obese and overweight individuals first turn to diet, fitness and medication to lose weight; however, these efforts alone are often not enough to keep weight at a level that is optimal for good health. Surgery is another increasingly viable alternative for those with a Body Mass Index (BMI) of greater than 40. In fact, the number of bariatric surgeries in the United States is projected to reach approximately 400,000 annually by 2010.4
Allergan has joined the effort to fight the growing obesity epidemic with a portfolio of innovative medical devices to help achieve and support sustained weight loss, reduce health risks associated with obesity and help patients realize their goals for healthy living and wellness. The LAP-BAND® Adjustable Gastric Banding System is the first adjustable medical device for individualized weight loss and the first minimally invasive surgical approach approved in the United States by the U.S. Food and Drug Administration. Approved outside of the United States, Allergan's portfolio also includes the BIB™ Intragastric Balloon System, which is a non-surgical alternative for the treatment of obesity.
Given the serious immediate and long-term consequences of the global obesity epidemic, we are committed to programs to prevent obesity. In that quest, we are actively pursuing the development of next-generation products and technologies capable of providing high-quality, healthier, and less traumatic long-term weight-loss treatment solutions.
Medical Aesthetics
Thanks to the many scientific advances in medicine over the last century, people are living longer, healthier lives. Yet individuals may feel that their outside appearance doesn't always match the vibrancy they feel on the inside. Environmental damage and the natural aging process lead some to seek science-based options.
Allergan's Total Rejuvenation™ portfolio is where science and aesthetics meet. The portfolio provides medical specialists and their patients with the most comprehensive, science-based aesthetic product offerings available. With the Natrelle® Collection, Allergan offers the industry's widest range of silicone gel and saline breast implant options for women seeking to enhance or restore their breast shape and form. We offer a comprehensive, science-based facial aesthetic portfolio that includes BOTOX® Cosmetic (onabotulinumtoxinA); the JUVÉDERM® family of dermal filler products; and physician-dispensed skin care products.
As a world leader in medical aesthetics, Allergan is and will remain deeply committed to the Science of Rejuvenation™. This means providing medical specialists and patients with products and information backed by science so they can make the best-informed medical aesthetics choices possible based on their own individual needs and treatment goals.
Indication
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in people 18 to 65 years of age for a short period of time (temporary).
IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects that can be life threatening. Call your doctor or get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:
Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice (dysphonia), trouble saying words clearly (dysarthria), loss of bladder control, trouble breathing, trouble swallowing.
There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines.
The dose of BOTOX® Cosmetic is not the same as, or comparable to, another botulinum toxin product.
Serious and or immediate allergic reactions have been reported. These reactions include itchy rash, swelling, and shortness of breath. Tell your doctor or get medical help right away if you experience any such symptoms, further injection of BOTOX® Cosmetic should be discontinued.
Do not take BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® or Dysport®; have a skin infection at the planned injection site.
Tell your doctor about all your muscle or nerve conditions such as amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease], myasthenia gravis or Lambert-Eaton syndrome as you may be at increased risk of serious side effects including severe dysphagia (difficulty swallowing) and respiratory compromise (difficulty breathing) from typical doses of BOTOX® Cosmetic.
Tell your doctor about all your medical conditions, including if you have: plans to have surgery; had surgery on your face; weakness of forehead muscles, such as trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (It is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to breastfeed (It is not known if BOTOX® Cosmetic passes into breast milk).
Medical Dermatology
Facing the world is not always easy for patients suffering from serious skin disorders. Dedicated to meeting the needs of these patients and their physicians, Allergan has developed some of the most technologically advanced dermatology products to treat skin disease as well as enhance the appearance of healthy skin.
According to the National Institutes of Health, between 5.8 and 7.5 million Americans suffer from psoriasis1, which is a chronic skin disorder than can take many different forms. An estimated 80 percent of all people between the ages of 11 and 30 have acne outbreaks at some point.2 Our dermatology portfolio includes TAZORAC® (tazarotene), the first topical receptor selective retinoid approved for psoriasis.
Another common chronic condition affecting an estimated 7.8 million Americans is hyperhidrosis, which is the term for excessive sweating.3 Patients with hyperhidrosis produce an amount of sweat that far exceeds that needed to regulate body temperature. Our medical dermatology portfolio includes BOTOX® (onabotulinumtoxinA) for severe primary axillary hyperhidrosis (excessive underarm sweating) that is not adequately managed by topical agents.
Urologics
At Allergan, we recognize the serious implications of urologic disorders including overactive bladder (OAB), a medical condition that affects 33 million Americans and is only expected to grow in prevalence as the population ages.1 In 2007, Allergan created a dedicated Urologics division within the organization to focus on meeting the needs of urologists and their patients.
Allergan is investing significant resources to develop a product portfolio that addresses the full continuum of care for patients with OAB and other urological and genitourinary disorders. Allergan's current product in this portfolio is SANCTURA XR®, a once-daily medication for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency approved in 2007 by the U.S. Food and Drug Administration.
In addition to our current products for OAB, we are continuing to research and develop new treatments for urologic disorders. Globally, we are currently in Phase III clinical trials investigating the use of BOTOX® (onabotulinumtoxinA) for the treatment of neurogenic OAB - that is, OAB secondary to multiple sclerosis or spinal cord injury, or other neurologic dysfunction. And we are in the midst of Phase II clinical trials of BOTOX® for idiopathic OAB (in which the cause is unknown) – by far the most common form of the disorder. In addition, Allergan is studying the use of BOTOX® neurotoxin in a Phase II clinical trial for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia, a non-cancerous disease of the prostate that can interfere with urination and is one of the most common diseases among men.
roduct Prescribing and Labeling Information
ACULAR® (ketorolac tromethamine ophthalmic solution) 0.5% (PDF)
ACULAR LS® (ketorolac tromethamine ophthalmic solution) 0.4% (PDF)
ACUVAIL® (ketorolac tromethamine ophthalmic solution) 0.45% (PDF)
ACZONE® (dapsone) Gel 5% (PDF)
ALOCRIL® (nedocromil sodium ophthalmic solution) 2% (PDF)
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15% (PDF)
AVAGE® (tazarotene) Cream 0.1% (PDF)
AZELEX® (azelaic acid cream) 20% (PDF)
BETAGAN® (levobunolol hydrochloride ophthalmic solution, USP) 0.5% (PDF)
BLEPH®-10 (sulfacetamide sodium ophthalmic solution, USP) 10% (PDF)
BLEPHAMIDE® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% (PDF)
BLEPHAMIDE® (sulfacetamide sodium − prednisolone acetate ophthalmic suspension, USP) 10%/0.2% (PDF)
BOTOX® (onabotulinumtoxinA) (PDF)
BOTOX® Cosmetic (onabotulinumtoxinA) (PDF)
COMBIGAN® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% (PDF)
ELESTAT® (epinastine HCl ophthalmic solution) 0.05% (PDF)
FLUOROPLEX® (fluorouracil) 1% Topical Cream (PDF)
FML® (fluorometholone ophthalmic ointment) 0.1% (PDF)
FML® (fluorometholone ophthalmic suspension, USP) 0.1% (PDF)
FML FORTE® (fluorometholone ophthalmic suspension) 0.25% (PDF)
JUVÉDERM® Ultra and JUVÉDERM® Ultra Plus (PDF)
JUVÉDERM® Ultra XC (PDF)
JUVÉDERM® Ultra Plus XC (PDF)
LASTACAFT™ (alcaftadine ophthalmic solution) 0.25% (PDF)
LATISSE® (bimatoprost ophthalmic solution) 0.03% (PDF)
LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) (PDF)
OCUFEN® (flurbiprofen sodium ophthalmic solution, USP) 0.03% (PDF)
OCUFLOX® (ofloxacin ophthalmic solution) 0.3% (PDF)
OZURDEX® (dexamethasone intravitreal implant) 0.7 mg (PDF)
POLY-PRED® (prednisolone acetate, neomycin sulfate, polymyxin B sulfate ophthalmic suspension) 0.5%/0.35% (PDF)
POLYTRIM® (polymyxin B sulfate and trimethoprim ophthalmic solution, USP) (PDF)
PRED FORTE® (prednisolone acetate ophthalmic suspension, USP) 1% (PDF)
PRED MILD® (prednisolone acetate ophthalmic suspension, USP) 0.12% (PDF)
PRED-G® (gentamicin and prednisolone acetate ophthalmic ointment, USP) 0.3%/0.6% (PDF)
PRED-G® (gentamicin and prednisolone acetate ophthalmic suspension, USP) 0.3%/1.0% (PDF)
PREVAGE® MD (PDF)
REFRESH CONTACTS® Contact Lens Comfort Drops (PDF)
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% (PDF)
SANCTURA® (trospium chloride) (PDF)
SANCTURA XR® (trospium chloride extended release capsules) (PDF)
TAZORAC® (tazarotene) Cream 0.05% and 0.1% (PDF)
TAZORAC® (tazarotene) Gel 0.05% and 0.1% (PDF)
ZYMAR® (gatifloxacin ophthalmic solution) 0.3% (PDF)
ZYMAXID™ (gatifloxacin ophthalmic solution) 0.5% (PDF)